Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer

Clinical Breast Cancer

Volumn 6, Issue 2, 2005, Pages 150-157

  Overmoyer, Beth ^a   Silverman, Paula ^a   Holder, Larry W ^b   Tripathy, Debasish ^c   Henderson, I Craig ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cancer Care Specialists of Central Illinois   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Efficacy; Hand foot syndrome; Left ventricular ejection fraction; Safety

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CELLULITIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PAIN; PERIODONTITIS; PETECHIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

EID: 22144455678     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.017     Document Type: Article

References (37)

1. Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg RA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1651-1717.
2. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67:801-805.
3. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15:3185-3191.
4. Lindley C. Breast cancer. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a Pathophysiologic Approach, 5th ed. Stamford, CT: Appleton & Lange, 2002:2223-2251.
5. Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002; 85:18-31.
6. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54(suppl 4):1-7.
7. Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: DeVita VT, Hellman S, Rosenberg RA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:415-431.
8. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54(suppl 4):15-21.
9. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89:1037-1047.
10. Perez AT, Domenech GH, Frankel C, et al. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: The Cancer Research Network, Inc., Experience. Cancer Invest 2002; 20(suppl 2):22-29.
11. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
12. Rivera E, Valero V, Syrewicz L, et al. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer [published erratum in J Clin Oncol 2004; 22:1534]. J Clin Oncol 2001; 19:1716-1722.
13. Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21:3249-3254.
14. Jones V, Finucane D, Rodriguez R, et al. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19:113a (Abstract #451).
15. Gogas H, Papadimitriou C, Kalofonos HP, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002; 13:1737-1742.
16. Rigatos SK, Tsavdaridis D, Athanasiadis A, et al. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study. Oncol Rep 2003; 10:1817-1819.
17. Vorobiof DA, Rapoport BL, Chasen MR, et al. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. Breast 2004; 13:219-226.
18. Sparano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001; 19:3117-3125.
19. Alexopoulos A, Karamouzis MV, Stavrinides H, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004; 15:891-895.
20. Athanassiou A, Potamianou A, Ziras N, et al. A phase II trial of docetaxel (D) and liposomal doxorubicin (LD) as 1st line treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22:74 (Abstract #297).
21. Gebbia V, Mauceri G, Fallica G, et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 2002; 63:23-30.
22. Ardavanis A, Kalbakis K, Malamos N, et al. The liposomal doxorubicin and vinorelbine (Navelbine) combination as salvage treatment for pretreated metastatic breast cancer (MBC). Preliminary analysis of a multicenter phase II trial. Proc Am Soc Clin Oncol 2003; 22:67 (Abstract #269).
23. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
24. Wolff AC, Bonetti M, Sparano JA, et al. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer: preliminary results of ECOG 3198. Proc Am Soc Clin Oncol 2003; 22:18 (Abstract #70).
25. Chia SK, Clemons M, Martin LA, et al. A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 23:34 (Abstract #630).
26. Edwards SJ. Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer. Semin Oncol Nurs 2003; 19(3 suppl 1):19-39.
27. Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14:1430-1437.
28. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454.
29. Nemoto T, Horton J, Simon R, et al. Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with Cytoxan, 5-FU and prednisone versus Cytoxan and Adriamycin, versus Cytoxan, 5-FU and Adriamycin, versus Cytoxan, 5-FU and prednisone alternating with Cytoxan and Adriamycin. Cancer 1982; 49:1988-1993.
30. Parvinen LM, Numminen S. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone. Acta Radiol Oncol 1985; 24:391-394.
31. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
32. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
33. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol 2003; 22:7 (Abstract #25).
34. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
35. 2. Ann Oncol 2000; 11:1029-1033.
36. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9:711-716.
37. Gabizon AA, Lyass O, Berry GJ, et al. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22:663-669.